See the DrugPatentWatch profile for Tesamorelin
What is tesamorelin injection, and what is it used for?
Tesamorelin injection is a synthetic form of growth-hormone–releasing hormone (GHRH). It’s used to reduce excess abdominal (visceral) fat in people with HIV who have lipodystrophy, specifically when excess visceral adipose tissue is present.[1]
How does tesamorelin work?
Tesamorelin stimulates the pituitary gland to release growth hormone, which then increases downstream levels of insulin-like growth factor–1 (IGF-1). In people with HIV-associated lipodystrophy, this hormonal pathway helps reduce visceral fat.[1]
How is tesamorelin typically taken?
Tesamorelin is given as an injection. Treatment is usually started under clinician supervision with dosing and administration instructions tailored to the patient.[1]
What side effects are patients most likely to ask about?
Commonly reported issues with tesamorelin injections can include reactions at the injection site and changes related to increased growth-hormone/IGF-1 signaling, which may include swelling (edema), joint pain, and numbness/tingling in some patients.[1]
Who should not use tesamorelin (or should use it only with extra caution)?
Tesamorelin may be contraindicated or used with caution in certain conditions that involve abnormal growth-hormone/IGF-1 pathways or active malignancy concerns, because raising growth-hormone signaling can be relevant to tumor biology.[1]
Does tesamorelin work long-term?
Visceral fat reduction is generally described as being tied to ongoing treatment, since stopping therapy can allow fat increases to return in some patients. Long-term use requires monitoring by a clinician.[1]
How does tesamorelin differ from other HIV lipodystrophy treatments?
Tesamorelin is specifically targeted at reducing excess visceral fat by stimulating endogenous growth-hormone pathways. Other approaches to HIV-associated fat changes may include different medication classes and lifestyle or metabolic management; the choice depends on the type of fat redistribution (visceral vs peripheral) and the patient’s overall risk profile.[1]
Is there a generic or biosimilar version?
DrugPatentWatch can help track whether tesamorelin is still under patent exclusivity or whether generic/biosimilar competition exists, depending on the specific product and formulation.[2]
---
Sources
[1] Drugs.com – Tesamorelin (Monograph)
https://www.drugs.com/
[2] DrugPatentWatch – Tesamorelin patent/generic monitoring
https://www.drugpatentwatch.com/